NCT05786430View on ClinicalTrials.gov

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Lazertinib/Pemetrexed/Carboplatin

Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05786430 - Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib | Biotech Hunter | Biotech Hunter